Table 3.
Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study after PSM
| Characteristics | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| OS | BCSS | OS | BCSS | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age at diagnosis (< 60 as ref.) | ||||||||
| ≥ 60 | 1.49 (1.20–1.85) | < 0.001 | 1 (0.78–1.289) | 0.987 | 1.6 (1.26–2.05) | < 0.001 | 1.23 (0.94–1.62) | 0.138 |
| Race (white as ref.) | ||||||||
| Black | 1.18 (0.89–1.60) | 0.243 | 1.22 (0.89–1.68) | 0.22 | 1.03 (0.77–1.39) | 0.842 | 0.95 (0.68–1.32) | 0.755 |
| Others | 0.96 (0.61–1.49) | 0.842 | 1.07 (0.66–1.73) | 0.798 | 1.09 (0.69–1.71) | 0.723 | 1.06 (0.65–1.74) | 0.813 |
| Marital status (single as ref.) | ||||||||
| Married | 0.7 (0.53–0.94) | < 0.05 | 0.62 (0.46–0.84) | < 0.01 | 0.68 (0.50–0.91) | 0.01 | 0.68 (0.49–0.95) | < 0.05 |
| Grade (G1 as ref.) | ||||||||
| G2 | 0.98 (0.48–2.01) | 0.958 | 0.8 (0.33–1.93) | 0.617 | 0.96 (0.47–1.98) | 0.918 | 0.8 (0.33–1.94) | 0.62 |
| G3 | 1.58 (0.84–2.97) | 0.155 | 1.8 (0.85–3.82) | 0.127 | 1.23 (0.65–2.32) | 0.529 | 1.26 (0.59–2.68) | 0.557 |
| G4 | 1.34 (0.64–2.80) | 0.439 | 1.58 (0.67–3.77) | 0.299 | 1.34 (0.64–2.81) | 0.443 | 1.44 (0.60–3.44) | 0.411 |
| ER status (negative as ref.) | ||||||||
| Positive | 0.82 (0.60–1.14) | 0.239 | 0.84 (0.59–1.21) | 0.353 | 0.83 (0.57–1.21) | 0.331 | 0.76 (0.50–1.15) | 0.19 |
| PR status (negative as ref.) | ||||||||
| Positive | 0.63 (0.43–0.93) | < 0.05 | 0.77 (0.51–1.15) | 0.204 | 0.67 (0.43–1.04) | 0.074 | 0.89 (0.56–1.42) | 0.627 |
| Stage T (≤ 5 cm as ref.) | ||||||||
| > 5 cm | 3.84 (3.08–4.78) | < 0.001 | 4.41 (3.44–5.66) | < 0.001 | 2.99 (2.31–3.86) | < 0.001 | 3.18 (2.39–4.24) | < 0.001 |
| Stage N (N0 as ref.) | ||||||||
| N1 | 1.56 (1.20–2.05) | 0.001 | 2.02 (1.51–2.71) | < 0.001 | 1.21 (0.91–1.61) | 0.191 | 1.43 (1.04–1.95) | < 0.05 |
| N2 | 2.91 (2.02–4.20) | < 0.001 | 3.29 (2.19–4.95) | < 0.001 | 1.84 (1.24–2.72) | < 0.01 | 1.82 (1.17–2.82) | < 0.01 |
| N3 | 3.27 (2.14–5.00) | < 0.001 | 4.04 (2.55–6.40) | < 0.001 | 2.2 (1.39–3.48) | 0.001 | 2.41 (1.46–3.98) | 0.001 |
| Breast operation (lumpectomy as ref.) | ||||||||
| Mastectomy | 2.6 (2.04–3.31) | < 0.001 | 3.18 (2.38–4.25) | < 0.001 | 1.46 (1.08–1.98) | < 0.05 | 1.52 (1.06–2.18) | < 0.05 |
| Chemotherapy (not done/unknown as ref.) | ||||||||
| Done | 0.84 (0.67–1.05) | 0.12 | 1.35 (1.02–1.80) | < 0.05 | 0.75 (0.58–1.00) | < 0.05 | 1.08 (0.79–1.48) | 0.617 |
| Radiotherapy (not done as ref.) | ||||||||
| Done | 0.62 (0.50–0.77) | < 0.001 | 0.65 (0.51–0.84) | < 0.001 | 0.64 (0.51–0.80) | < 0.001 | 0.64 (0.50–0.83) | 0.001 |
| Axilla LN operation (SLNB as ref.) | ||||||||
| ALND | 1.89 (1.49–2.39) | < 0.001 | 2.22 (1.68–2.92) | < 0.001 | 1.17 (0.89–1.54) | 0.254 | 1.16 (0.85–1.60) | 0.347 |
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection
Significant results are in italic